USPSTF: 'No' for all PSA screening for prostate cancer

Share this article:
USPSTF: 'No' for all PSA screening for prostate cancer
USPSTF: 'No' for all PSA screening for prostate cancer

The United States Preventive Services Task Force (USPSTF) has issued a final recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer for all men, regardless of age. The recommendation, published by Annals of Internal Medicine, updates the group's 2008 recommendations, in which the Task Force members had concluded that there was no evidence to support PSA screening for men older than 75 years. 

The USPSTF based its latest guidance on a review of evidence published since 2008, finding that the harms of PSA testing outweigh the benefits for men of any age. (The task force considers health benefits and harms, but not costs, when developing its recommendations.) As noted in a statement issued by the American College of Physicians, the organization that publishes Annals of Internal Medicine, strong evidence shows that PSA screening is associated with significant harms, such as suffering lifelong urinary incontinence, bowel dysfunction, and erectile dysfunction after undergoing early treatment for PSA-detected prostate cancer, as nearly 90% of men do. 

Two major trials of PSA testing in asymptomatic men informed that decision. In one, conducted in the United States, screening did not reduce prostate cancer mortality. In the other study, conducted in seven European countries, approximately one death was prevented for every 1,000 men, aged 55 to 69 years, who were screened, mostly in two countries. Five countries did not find a statistically significant reduction in deaths.

In an accompanying editorial, William J. Catalona, MD, and coauthors charged that the USPSTF underestimated the benefits and overestimated the harms of using PSA-based screening for prostate cancer, and that the recommendation was based on flawed studies with inadequate follow-up time. Catalona is medical director of the Urological Research Foundation in St. Louis, Missouri, and was the developer of the prostate-specific antigen test for prostate cancer screening. ONA

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in In the News

Navigator Notes: Distress screening and support

Navigator Notes: Distress screening and support

As patients and oncology care teams strive to keep up with complex treatment plans, symptoms of distress in the patient may be missed. Distress screening tools can help nurse navigators ...

Out-of-pocket costs influence adherence to treatment

Out-of-pocket costs influence adherence to treatment

Many patients skip doses or stop taking medication entirely when their share of the costs becomes too high.

Cancer deaths continue to decline

Cancer deaths continue to decline

The American Cancer Society (ACS) has published its latest annual report on cancer incidence and mortality, and the news is good.